Helix BioPharma (TSE:HBP) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Helix BioPharma Corp. has received a U.S. patent for its innovative L-DOS47 platform, which targets tumors with high CEACAM6 expression, potentially enhancing cancer treatment outcomes. This development strengthens Helix’s position in the oncology market, offering new hope for patients with hard-to-treat cancers.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
